![]() ![]() ![]() Patt testified before the Texas Legislature in 2021 in support of the gold-carding law. Serving as vice president of the Community Oncology Alliance, immediate past president of the Texas Society of Clinical Oncology and a past chair of the Texas Medical Association (TMA) Council on Legislation, Dr. Patt had hoped that a landmark “gold card” law enacted there would have a swift effect to help lessen the maddening care impact of prior authorization. Find out how the AMA is tackling prior authorization with research, practice resources and reform resources.īuilding the case for reform Building the case for reform Prior authorization is overused and existing processes present significant administrative and clinical concerns. So for it to be so difficult for me to get my patients what they need is really quite challenging.”įixing prior authorization is a critical component of the AMA Recovery Plan for America’s Physicians. I know a lot of data about breast cancer. I'm a national principal investigator on trials. “I've been a breast medical oncologist for 16 years. Patt, who took part in a panel discussion on fixing prior authorization at the 2023 AMA State Advocacy Summit. “It's frustrating and, honestly demoralizing as a doctor,” added Dr. Patt’s own team has two people assigned to that task-with one handling imaging prior auth requests and another to shepherd therapy-related prior authorizations. Patt, a partner and the executive vice president of with Texas Oncology, a private medical practice with 220 locations that sees 70,000 new cancer patients a year.Īlong with 520 physicians, the group has about 175 people on staff whose sole job is managing prior authorization requests. “It's incredibly frustrating for her-and for patients more broadly-because they feel like they don't have any control over what's going to happen, what their journey is going to look like,” said Dr. So by delaying her care, the insurance company dramatically worsened the woman’s quality of life. When the insurance company denied that course of treatment, she prescribed a more standard chemotherapy regime, which-because of related toxicities-made it impossible for her patient to keep working. Patt thought her patient was a good candidate for a promising new regimen known as MonarcHER. “She would clinically deteriorate in that time.”ĭr. “Six weeks was an unacceptable amount of time,” said Dr. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |